Is Vincaleukoblastine, 22-oxo- Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Vincaleukoblastine, 22-oxo-? Is Vincaleukoblastine, 22-oxo- safe for nursing mother and child? Does Vincaleukoblastine, 22-oxo- extracts into breast milk? Does Vincaleukoblastine, 22-oxo- has any long term or short term side effects on infants? Can Vincaleukoblastine, 22-oxo- influence milk supply or can Vincaleukoblastine, 22-oxo- decrease milk supply in lactating mothers?
Vincaleukoblastine, 22-oxo- lactation summary
- DrLact safety Score for Vincaleukoblastine, 22-oxo- is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of Vincaleukoblastine, 22-oxo- may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that Vincaleukoblastine, 22-oxo- may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Vincaleukoblastine, 22-oxo- .
- Usage of Vincaleukoblastine, 22-oxo- is in contradiction to breastfeeding hence if it is must to use Vincaleukoblastine, 22-oxo- and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Vincaleukoblastine, 22-oxo- usage in lactation
Drug is cleared from the body in 5 elimination half-lives. Return to breastfeeding is likely safe after 35 days of pumping-discarding of the milk.
Answer by DrLact: About Vincaleukoblastine, 22-oxo- usage in lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] It is probably impractical to resume breastfeeding after Vincaleukoblastine, 22-oxo- therapy because of the drug's long half-life. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2]
Vincaleukoblastine, 22-oxo- Side Effects in Breastfeeding
In a 4-month-old, neutropenia was probably caused by cyclophosphamide in a mother 9 days after the last of 6 weekly doses of 800 mg cyclophosphamide intravenously, 2 mg Vincaleukoblastine, 22-oxo- intravenously and daily doses of 30 mg of prednisolone orally. Neutropenia persisted at least 12 days and was accompanied by a brief episode of diarrhea.[3] The contribution of Vincaleukoblastine, 22-oxo- to the neutropenia cannot be determined.
Alternate Drugs
Bevacizumab(Low Risk)
Bleomycin(Dangerous)
Docetaxel(Dangerous)
Cisplatin(Unsafe)
Pazopanib(Unsafe)
Vinorelbine(Dangerous)
Busulfan(Dangerous)
Trastuzumab(Unsafe)
Dacarbazine(Dangerous)
Imatinib(Unsafe)
Thioguanine(Dangerous)
Erlotinib(Unsafe)
Cladribine(Dangerous)
Azelaic Acid(Safe)
Letrozole(Dangerous)
Dasatinib(Unsafe)
Exemestane(Dangerous)
Vincristine(Dangerous)
Nilotinib(Unsafe)
Tamoxifen(Dangerous)
Dactinomycin(Dangerous)
Ipilimumab(Unsafe)
Mitoxantrone(Dangerous)
Cetuximab(Unsafe)
Mercaptopurine(Safe)
Carboplatin(Dangerous)
Paclitaxel(Dangerous)
Hydroxyurea(Low Risk)
Fluorouracil(Dangerous)
Etoposide(Dangerous)
Gemcitabine(Dangerous)
Alemtuzumab(Low Risk)
Nivolumab(Unsafe)
Doxorubicin(Dangerous)
Rituximab(Low Risk)
Vinblastine(Dangerous)
Cyclophosphamide(Dangerous)